Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Our Role & Impact > Advocacy > Current Actions

| More

Current Actions

FDA Review of Olaparib

On June 25, 2014 the Oncologic Drugs Advisory Committee (ODAC) of the FDA discussed AstraZeneca Pharmaceuticals' new drug application for olaparib capsules as maintenance treatment of patients with platinum-sensitive relapsed ovarian cancer who have completed chemotherapy. FORCE presented oral commentary supporting approval of this application, and has been a strong proponent of PARP inhibitor research. Read more...

Participation in Amicus Regarding SCOTUS Oral Contraception Cases

In March 2014, the Supreme Court heard two cases, the Hobby Lobby case and the Conestoga Wood case, about birth control coverage under the Affordable Care Act (ACA).  ACA mandates coverage of several preventative services with no cost sharing, one of which is birth control.  In these cases, the companies asserted that the mandate infringes on their religious rights under the Religious Freedom Restoration Act.  On July 2, 2014 the Court ruled thatsome family-owned or other closely held businesses can opt out of the federal requirement to pay for contraceptives in health coverage for their workers.FORCE supports coverage of oral contraceptives as it is one of the only nonsurgical options for decreasing a women's risk of ovarian cancer.  For the HBOC community, this is a women’s health issue. FORCE joined the Ovarian Cancer National Alliance and others in submitting an amicus brief on this issue. Visit the National Women's Law Center or the Ovarian Cancer National Alliance for more information on this topic.

USPSTF Guidelines for BRCA Risk Assessment, Genetic Counseling, and Genetic Testing

The United States Preventive Services Task Force (USPSTF) is a panel of experts in prevention and evidence-based medicine which conducts scientific reviews of and develops recommendations on the effectiveness of a broad range of preventive services. In December 2013, the USPSTF released new guidelines for Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women. Read more...

Myriad Genetics Patent Infringement Lawsuit and Preliminary Injunction Against Ambry and Gene-by-Gene

In June 2013, the US Supreme Court invalidated Myriad's patents on the BRCA1 and BRCA2 genes. Since then, a number of laboratories began offering genetic tests for BRCA mutations at a lower cost than Myriad. Myriad filed suit against most of these companies, alleging their BRCA tests infringe on patents not invalidated by the Supreme Court decision. Myriad asked the court to block Ambry and Gene by Gene from BRCA testing until the patent infringement case is resolved. Read more...

FDA's Patient-Focused Drug Development Program

The FDA's Prescription Drug User Fee Act (PDUFA) authorized the FDA to choose 20 different disease areas for concentration to expedite drug development and review. FORCE, in partnership with other hereditary cancer advocacy groups, provided written and oral testimony urging the FDA to add inherited cancer syndromes to the disease focus list. The FDA ultimately chose breast cancer as one of the disease areas. Read more...

Learn about our accomplishments and how you can help.

Recognize a Loved One

The FORCE Research Advocate Training (FRAT) Program is a basic educational course aimed at preparing people to become engaged in research advocacy on behalf of the hereditary breast and ovarian cancer community.

Personal Fundraising

FORCE is proud of the progress we have made in support, research and advocacy that better the lives or our community.